Intellia Therapeutics Secures $400M Loan Facility
Intellia Therapeutics (NTLA) has secured a $400 million non-dilutive senior secured term loan facility with OrbiMed. The financing is intended to provide financial flexibility as the company advances its drug candidate, lonvoguran ziclumeran (lonvo-z), toward U.S. approval and commercial launch for hereditary angioedema. This funding arrangement avoids equity dilution, which could be favorable for existing shareholders. It supports Intellia’s ongoing development efforts without issuing new shares.
Tickers: $NTLA
Topics: biotech financing hereditary angioedema